|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,923,564: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 7,923,564, granted on April 12, 2011, to ImmunoGen, Inc., covers a specific class of antibody-drug conjugates (ADCs) designed for targeted cancer therapy. The patent particularly claims novel linker-payload combinations that enhance stability and specificity, facilitating improved therapeutic indices. This analysis dissects the scope and claims to understand the patent’s breadth, core inventive concepts, and its position within the patent landscape of ADCs and related targeted therapies.
What Is the Scope of U.S. Patent 7,923,564?
Scope refers to the breadth of legal protection conferred by the patent’s claims.
The patent claims cover:
- Linker-payload combinations specifically engineered for stable, targeted delivery.
- Antibody conjugates directed against specific tumor-associated antigens.
- Methods of preparing such conjugates and their use in therapeutic applications.
The scope is primarily centered on:
- Linkers that are cleavable or non-cleavable but optimized for stability.
- Payloads comprising cytotoxic agents, especially maytansinoids or auristatins.
- Conjugates targeting various antigens, with flexibility for modifications.
Key points:
| Aspect |
Details |
Implication |
| Focus on linker chemistry |
Emphasis on cleavable/different stability profiles |
Broad coverage of linker types |
| Payload diversity |
Cytotoxic agents like maytansinoids, auristatins |
Extends to multiple payload classes |
| Antigen targeting |
Specific or generic tumor-associated antigens |
Broad application across cancer types |
What Do the Claims Cover Specifically?
Independent Claims
-
Claim 1: An antibody-drug conjugate comprising:
- An antibody specific for a tumor-associated antigen;
- A linker covalently attached to the antibody;
- A cytotoxic payload attached to the linker;
- The linker having particular chemical features, such as a cleavable thiol-maleimide linkage with defined stability characteristics.
-
Claim 12: A method for preparing such an ADC, involving conjugation steps that control the ratio of drug to antibody (DAR), often specified as approximately 2–4.
Dependent Claims
Dependent claims specify:
- Variations in linker chemistry (e.g., disulfide-based, peptide-based, etc.).
- Specific payload molecules with chemical structures or functional groups.
- Particular antibody subclasses or modifications.
- Methods for enhancing stability or reducing off-target effects.
How Does the Patent Fit in the Broader ADC Landscape?
| Patent Landscape Element |
Details |
Implications for Innovation |
| Linker Innovations |
Focus on cleavable linkers with optimized stability |
Expanding ADC therapeutic window |
| Payload Diversity |
Use of maytansinoids, auristatins, other cytotoxins |
Compatibility with multiple payloads |
| Targeting Antigens |
Primarily tumor-associated antigens like HER2, CD37, CD22 |
Cross-applicability across cancers |
| Conjugation Techniques |
Site-specific conjugation, DAR control |
Improved reproducibility and efficacy |
Positioning:
The patent aligns with early innovations in ADCs post-2000s, when monoclonal antibodies and potent cytotoxins converged into targeted biologics. It supports a broad platform for conjugates with adaptable linkers and payloads, contributing to both first-generation and subsequent derivative ADCs.
Comparison with Related Patents and Patent Families
| Patent |
Assignee |
Issue Date |
Focus |
Differences with 7,923,564 |
Status |
| US 8,107,065 |
ImmunoGen |
2012 |
Additional linker chemistries |
Broader linker types, more payloads |
Active |
| US 8,320,720 |
ImmunoGen |
2012 |
Site-specific conjugation |
Sensitive to conjugation site |
Active |
| US 9,168,592 |
Genentech |
2015 |
Herceptin conjugates |
Focus on specific antibodies |
Active |
Observation:
U.S. Patent 7,923,564 forms part of a patent family with multiple continuations and improvements that collectively cover a broad spectrum of ADC configurations. ImmunoGen’s IP estate encompasses linker chemistry, conjugation techniques, and payload modifications.
Key Patent Elements and Claims Analysis
Claim Scope
| Claim # |
Claim Type |
Main Feature |
Potential Overlaps |
Limitations |
| 1 |
Independent |
ADC with specific linker-payload structure |
Similar ADCs with different linkers |
Defined chemical features restrict scope |
| 12 |
Independent |
Conjugate preparation method |
Similar methods with modifications |
Specific conjugation conditions |
Novelty and Inventive Step
- The patent emphasizes stability of linker-payload bonds, particularly involving thiol-maleimide linkages with controlled release profiles.
- Demonstrates inventive step over prior art by specific linker design that improves serum stability and controlled release at target sites.
Patent Landscape Summary
Field: Targeted cancer therapeutics via ADCs
Assignees: ImmunoGen, Inc. (notably), Genentech (via licensing or patenting efforts)
Coverage Timing: Early 2000s to mid-2010s, with continuous filings and continuations
Legal Status: Active and licensed in multiple jurisdictions, with recent continuations extending coverage
Key Patent Families:
- Linker chemistry innovations
- Conjugation techniques for DAR control
- Payload engineering for enhanced potency and safety
Competitive Position:
Provides foundational intellectual property underpinning several marketed ADCs, including Kadcyla (ado-trastuzumab emtansine).
Deep Dive: Specific Claims and Examples
| Claim |
Description |
Scope |
Practical Implication |
| Claim 1 |
An ADC with a cleavable linker covalently attached to a monoclonal antibody and a cytotoxic payload |
Broad, covering multiple linker chemistries, payloads, and targets |
Can be used to develop various cancer therapies targeting different antigens |
| Claim 5 |
The linker features a disulfide bond stabilized by specific substituents |
Specificity enhances serum stability |
Addresses stability issues in circulation |
| Claim 12 |
Conjugation method employing controlled drug-to-antibody ratio |
Reproducibility and manufacturing consistency |
Facilitates commercial scaling and quality control |
Critical Analysis of Patent Strengths and Limitations
| Strengths |
Limitations |
| Broad protection of linker-payload chemistries |
Patent claims narrowly focused on certain chemical features |
| Includes both compositions and methods |
May face challenges if alternative linkers or conjugation methods emerge |
| Key role in patenting early-stage ADCs |
Patent landscapes have become crowded with similar innovations |
Key Takeaways
- Patent Scope: U.S. Patent 7,923,564 provides extensive coverage over linker-payload combinations for ADCs, focusing on stability and controlled release. Its claims encompass various chemical modifications, making it a fundamental IP asset in ADC development.
- Patent Landscape Position: It forms a core part of ImmunoGen's IP estate, contributing to the foundational technology for marketed ADCs such as Kadcyla. It has been integrated into broader patent families spanning conjugation chemistry, payload design, and targeting strategies.
- Implications for Developers: Companies seeking to innovate or enter the ADC space must navigate this patent’s claims carefully, ensuring non-infringement or licensing. Its broad claims necessitate inventive design around the disclosed linker chemistries and conjugation methods.
- Legal and Commercial Relevance: The patent’s duration extends into the 2030s, offering a significant competitive moat in ADC technology. Infringements or licensing negotiations revolve around its specific linker and conjugation claims.
FAQs
-
What specific types of linkers are covered by U.S. Patent 7,923,564?
The patent covers cleavable and non-cleavable linkers, particularly emphasizing disulfide and peptide-based linkages with enhanced stability, but the claims are sufficiently broad to encompass various chemical linker structures with specified stability features.
-
How does U.S. Patent 7,923,564 influence the development of new ADCs?
It establishes a broad legal scaffold for linker-payload technology, requiring subsequent developers to design around or license the patented chemistry, thus shaping strategic R&D pathways.
-
Can the claims be challenged or invalidated?
Given the patent's age, prior art searches and legal challenges could potentially narrow or invalidate certain claims, especially if newer, non-obvious linkers or conjugation methods emerge that differ substantively from those claimed.
-
Does this patent cover all ADCs targeting cancer?
No. While it provides broad coverage technically, the patent is specific to certain linker-payload chemistries, and ADCs with fundamentally different chemistry or technologies may not infringe.
-
What is the importance of this patent in the current ADC market?
It remains critical, underpinning key innovations used in FDA-approved ADCs, and influences patent strategies and licensing negotiations for ongoing and future ADC research.
References
- U.S. Patent 7,923,564, ImmunoGen, Inc., April 12, 2011.
- US Patent Family Portfolio related to ADCs, ImmunoGen public filings.
- "Antibody-Drug Conjugates: The Development of Targeted Cancer Therapy," Nature Reviews Drug Discovery, 2018.
- "Linker Technologies for ADCs," Journal of Controlled Release, 2020.
Note: The detailed patent claims, legal status, and technical specifics should be reviewed directly from the patent document for legal accuracy and richer technical insights.
More… ↓
⤷ Start Trial
|
